AAM Urges Congress To Re-evaluate Blocking Act
Report Claims Legislation Could Cost $1.7bn For Each Generic Delayed
Pointing out the “critical shortcomings of the Blocking Act” in a new report, the AAM has urged the US Congress to re-evaluate the legislation.
You may also be interested in...
Trade association’s CEO says a new strategic planning initiative will consider among other things how gene therapy could fit into the generic industry business model.
A proposed US House bill that would prevent the first generic filer to challenge patents listed against the reference brand from ‘parking’ their 180-day market exclusivity has once again come under fire from the AAM.
Dan Leonard is working on post-pandemic generic drug issues, using coronavirus as a way to get in front of lawmakers.